Current aspects of polycystic ovary syndrome I: definition, pathophysiology, clinical manifestations, diagnosis and complications

1. Kun IZ. Klinikai endocrinologia. Erdélyi Múzeum Egyesület, Kolozsvár; 2000. p. 421–30, 296–303.Search in Google Scholar

2. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 1935; 29:181–91.10.1016/S0002-9378(15)30642-6Open DOISearch in Google Scholar

3. Geisthövel F, Rabe T. The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis. Reprod. Biomed. Online. Elsevier; 2007;14:522–35.1742583810.1016/S1472-6483(10)60902-9Search in Google Scholar

4. Stracquadanio M, Ciotta L. Metabolic Aspects of PCOS. Cham: Springer International Publishing; 2015; 5-2010.1007/978-3-319-16760-2_2Search in Google Scholar

5. Cobin R, Futterweit W, Nestler J, Reaven G, Jellinger P, Handelsman Y, et al. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr. Pract. 2005;11:125–34.10.4158/EP.11.2.125Search in Google Scholar

6. Homburg R. Pregnancy complications in PCOS. Best Pract. Res. Clin. Endocrinol. Metab. 2006;20:281–92.10.1016/j.beem.2006.03.00916772158Open DOISearch in Google Scholar

7. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1. Endocr. Pract. 2015;21:1291–300.10.4158/EP15748.DSCSearch in Google Scholar

8. Lakatos P, Gimes G, Speer G. A PCOS klinikai képe felnőttben. In: Lakatos P, Speer G, editors. Policisztás ovarium szindróma. Budapest: Semmelweis Kiadó; 2009. p. 47–66.Search in Google Scholar

9. Speer G. A PCOS patogenezise és epidemiológiája. In: Lakatos P, Speer G, editors. Policisztás ovarium szindróma. Budapest: Semmelweis Kiadó; 2009. p. 29–46.Search in Google Scholar

10. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014;171:P1–29.10.1530/EJE-14-025324849517Search in Google Scholar

11. Dimitriadis GK, Kyrou I, Randeva HS. Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines. Curr. Pharm. Des. 2016;22:5535–46.10.2174/138161282266616072610313327464726Open DOISearch in Google Scholar

12. Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch. Gynecol. Obstet. 2017;296:405–19.10.1007/s00404-017-4429-2Search in Google Scholar

13. Morrison SA, Goss AM, Azziz R, Raju DA, Gower BA. Perimuscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome. Hum. Reprod. Oxford University Press; 2016;32:185–92.10.1093/humrep/dew279Search in Google Scholar

14. Borsos A, Jakab A. Polycysticus ovarium szindróma. In: Leövey A, Nagy VE, Paragh Gy RK, editors. Az endokrin és anyagcserebetegségek Gyak. kézikönyve. Medicina, Budapest; 2011. p. 388–92.Search in Google Scholar

15. Kun IZ, Szántó Z. Neuroendocrinologia. Kolozsvár: Erdélyi Múzeum Egyesület; 2012.Search in Google Scholar

16. Kun IZ, Szántó Z. Mi változott a metabolikus szindróma értelmezésében, diagnózisában és kórtanában az utóbbi huszonöt évben ? Orvostudományi Értesítő. 2013;88:53–68.Search in Google Scholar

17. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 2005;62:37–43.10.1111/j.1365-2265.2004.02170.x15638868Open DOISearch in Google Scholar

18. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf). 2008;69:634–41.10.1111/j.1365-2265.2008.03247.xSearch in Google Scholar

19. Charikleia C, Frangiskos E, Sarantis L, Christina P, Christos A, Evangelos M, et al. Strong and positive association of Endothelin-1 with AGEs in PCOS: A causal relationship or a bystander? Hormones. 2011;10:292–7.10.14310/horm.2002.1320Search in Google Scholar

20. Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens). 13:65–73.10.1007/BF0340132124722128Search in Google Scholar

21. Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, et al. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 1996;104 Suppl 4:715–40.10.1289/ehp.96104s471514696758880000Search in Google Scholar

22. Akın L, Kendirci M, Narin F, Kurtoglu S, Saraymen R, Kondolot M, et al. The endocrine disruptor bisphenol A may play a role in the aetiopathogenesis of polycystic ovary syndrome in adolescent girls. Acta Paediatr. 2015;104:e171–7.10.1111/apa.1288525469562Search in Google Scholar

23. Eslami B, Rashidi BH, Amanlou M, Lak TB, Ghazizadeh M, Haghollahi F, et al. The Association Between Bisphenol A and Polycystic Ovarian Syndrome: A Case-Control Study. Acta Med Iran. 2017;55:759–64.Search in Google Scholar

24. Tarantino G, Valentino R, Somma C Di, D’Esposito V, Passaretti F, Pizza G, et al. Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin. Endocrinol. (Oxf). 2013;78:447–53.10.1111/j.1365-2265.2012.04500.x22805002Open DOISearch in Google Scholar

25. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell Biol. 2007;127:581–9.10.1007/s00418-006-0265-3Search in Google Scholar

26. Garg D, Merhi Z. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? Nutrients. Multidisciplinary Digital Publishing Institute (MDPI); 2015;7:10129–44.10.3390/nu7125524469007626690206Search in Google Scholar

27. Manikkam M, Guerrero-Bosagna C, Tracey R, Haque MM, Skinner MK. Transgenerational Actions of Environmental Compounds on Reproductive Disease and Identification of Epigenetic Biomarkers of Ancestral Exposures. Shioda T, editor. PLoS One. Public Library of Science; 2012;7:e31901.10.1371/journal.pone.0031901328963022389676Search in Google Scholar

28. López de Alda MJ, Barceló D. Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by liquid chromatography–diode array detection–mass spectrometry. J. Chromatogr. A. Elsevier; 2000;892:391–406.10.1016/S0021-9673(00)00068-6Search in Google Scholar

29. Gervais G, Bichon E, Antignac J-P, Monteau F, Leroy G, Barritaud L, et al. Differential global profiling as a new analytical strategy for revealing micropollutant treatment by-products: Application to ethinylestradiol and chlorination water treatment. Chemosphere. Pergamon; 2011;83:1553–9.10.1016/j.chemosphere.2011.01.027Search in Google Scholar

30. Da Ros CT, Graziottin TM. Environmental Issues Resulting in Hypogonadism in Brazilian Men. Bioenvironmental Issues Affect. Men’s Reprod. Sex. Heal. Elsevier; 2018. p. 33–40.10.1016/B978-0-12-801299-4.00002-5Search in Google Scholar

31. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J. Clin. Psychopharmacol. 2004;24:322–34.10.1097/01.jcp.0000125745.60149.c615118487Search in Google Scholar

32. Kun IZ, Szántó Z, Kun I, Kolcsár M. Konvencionális és atípusos antipszichotikumok okozta metabolikus szindróma. Orvostudományi Értesítő. 2017;90:7–18.Search in Google Scholar

33. Saydam B, Yildiz B. Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome. Curr. Pharm. Des. 2016;22:5572–87.10.2174/138161282266616071514393327426125Open DOISearch in Google Scholar

34. Abbott DH, Nicol LE, Levine JE, Xu N, Goodarzi MO, Dumesic DA. Nonhuman primate models of polycystic ovary syndrome. Mol. Cell. Endocrinol. Elsevier Ireland Ltd; 2013;373:21–8.10.1016/j.mce.2013.01.013Search in Google Scholar

35. Dumesic DA, Goodarzi MO, Chazenbalk GD, Abbott DH. Intrauterine environment and polycystic ovary syndrome. Semin. Reprod. Med. 2014;32:159–65.10.1055/s-0034-1371087Search in Google Scholar

36. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women. J. Clin. Endocrinol. Metab. 1994;79:1328–33.10.1210/jcem.79.5.7962325Search in Google Scholar

37. Rosenfield RL. Adolescent anovulation: Maturational mechanisms and implications. J. Clin. Endocrinol. Metab. 2013;98:3572–83.10.1210/jc.2013-1770376396923913942Search in Google Scholar

38. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, et al. Obesity and sex steroid changes across puberty: Evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J. Clin. Endocrinol. Metab. 2007;92:430–6.10.1210/jc.2006-2002219613417118995Open DOISearch in Google Scholar

39. van Hooff MHA, Voorhorst FJ, Kaptein MBH, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum. Reprod. 2004;19:383–92.10.1093/humrep/deh079Search in Google Scholar

40. Witchel SF, Tena-Sempere M. The Kiss1 system and polycystic ovary syndrome: lessons from physiology and putative pathophysiologic implications. Fertil. Steril. 2013;100:12–22.10.1016/j.fertnstert.2013.05.02423809625Search in Google Scholar

41. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr. Rev. The Endocrine Society; 2016;37:467–520.10.1210/er.2015-1104Search in Google Scholar

42. Speer G, Lakatos P. A PCOS diagnózisa. In: Lakatos P, Speer G, editors. Policisztás ovarium szindróma. Budapest: Semmelweis Kiadó; 2009. p. 67–72.Search in Google Scholar

43. Azziz R. Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature. J. Clin. Endocrinol. Metab. Oxford University Press; 2006;91:781–5.10.1210/jc.2005-215316418211Open DOISearch in Google Scholar

44. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. JCEM. 2006;91:4237–45.10.1210/jc.2006-017816940456Search in Google Scholar

45. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum. Reprod. 2011;26:3123–9.2192605410.1093/humrep/der29721926054Search in Google Scholar

46. Tal R, Seifer DB, Khanimov M, Malter HE, Grazi R V, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am. J. Obstet. Gynecol. Elsevier Inc; 2014;1–8.10.1016/j.ajog.2014.02.02624593938Search in Google Scholar

47. Cassar S, Teede HJ, Moran LJ, Joham AE, Harrison CL, Strauss BJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin. Endocrinol. (Oxf). 2014;10.1111/cen.1255725040369Open DOISearch in Google Scholar

48. Insler V, Barash A, Shoham Z, Koistinen R, Seppala M, Hen M, et al. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease. Isr. J. Med. Sci. 1994;30:42–7.Search in Google Scholar

49. Prelević GM, Wurzburger MI, Balint-Perić L, Ginsburg J. Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries. Horm. Res. Karger Publishers; 1992;37:125–31.10.1159/000182296Search in Google Scholar

50. Kun IZ, Kun I, Kun IZJ. Metabolikus szindróma, diabetes mellitus és a rosszindulatú daganatok. Orvostudományi Értesítő. 2015;88:7–18.Search in Google Scholar

51. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. The Endocrine Society; 2010;95:4133–60.10.1210/jc.2009-2631Search in Google Scholar

52. Bajnok L, Kemény J, Molnár M, Sipos M, Speer G, Tabák R, et al. A PCOS szövődményei. In: Lakatos P, Speer G, editors. Policisztás ovarium szindróma. Semmelweis Kiadó, Budapest; 2009. p. 130.Search in Google Scholar